4.4 Review

Recent advances in nontoxic Escherichia coli heat-labile toxin and its derivative adjuvants

Journal

EXPERT REVIEW OF VACCINES
Volume 15, Issue 11, Pages 1361-1371

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14760584.2016.1182868

Keywords

Heat-labile enterotoxin; adjuvant; immune; ADP-ribosylation; nontoxic; vaccine; adjuvant

Categories

Funding

  1. Natural Science Foundation of China (NSFC) [30972585]
  2. State Key Laboratory of Pathogen and Biosecurity (SKLPBS) [1523]

Ask authors/readers for more resources

Introduction: The nontoxic heat-labile enterotoxin (LT) of Escherichia coli and the B subunit of LT (LTB) have been extensively studied as potent vaccine adjuvants.Areas covered: This review covers the area of enterotoxin based vaccine adjuvant and summarizes the development of nontoxic LT mutant (mLT) and LTB and their potency as oral, parenteral and injection adjuvants. Recent evidences indicated that the mechanism of LTB adjuvanticity was to enhance the turnover of dendritic cells (DCs) in spleen and increase DCs capacity to perform as antigen presentation cells (APCs) encountered with T cells. LTB also induces B and T cells clustering and delay/arrest in T-cell division following endocytosis or B-cell receptor (BCR) uptaking of antigen in a ganglioside-mediated manner.Expert commentary: It is pointed out that the immunogenicity of LTB (or LT) is more important than the receptor binding property (or ADP-ribosylation activity) for the adjuvanticity of LT toxoid. The immunogenicity of LTB (or LT) might confer unknown characteristics to maintain LT toxoid adjuvanticity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available